Browse the evidence

Over half of patients with type 2 diabetes fail to meet glycemic targets due to clinical inertia.

Practitioners should be aware of the impact of clinical inertia on treatment outcomes.

Microneedle (MN)-based technologies provide a painless drug delivery approach that targets adipose tissue directly, minimizing systemic exposure and reducing the required dosage.

Practitioners may consider MNs as a viable alternative for delivering anti-obesity medications effectively.

The use of nano-based medications through transdermal delivery is important for effective obesity treatment.

Practitioners should consider incorporating nano-based medications for better treatment outcomes.

Tirzepatide's effect is largely mediated by its GIP component.

Understanding that GIP mediates tirzepatide's effects can help practitioners optimize treatment strategies.

Tirzepatide has a half-life of five days, allowing for once-weekly administration.

Practitioners can schedule tirzepatide administration once a week due to its five-day half-life.

Powerlifters exhibited significantly less shoulder extension and horizontal abduction, and hip flexion, extension, and adduction than recreationally strength-trained men.

Powerlifters may need to address limitations in shoulder and hip ROM to optimize performance.

No statistically significant differences in resting blood variables or body composition were observed between the AEL and TRAD protocols after 4 weeks of training.

Practitioners may not expect significant changes in hormonal responses or body composition from AEL compared to traditional training.

Results marginally favored the use of AEL, but did not support significant improvements in body composition or hormonal responses.

AEL may have slight advantages, but practitioners should not expect major changes in outcomes.

Canagliflozin has shown benefits in reducing progression of renal disease and heart failure in patients with type 2 diabetes.

Canagliflozin may be a beneficial treatment option for managing renal and heart health in diabetic patients.

The combination of canagliflozin and metformin in a single tablet may improve medication adherence in type 2 diabetes.

Using a fixed-dose combination may enhance patient compliance with diabetes treatment regimens.

The goal of management in T2D patients with significant fibrosis is to slow the progression of liver disease and reduce associated clinical events.

Clinicians should aim to adapt therapies to manage liver disease progression in diabetic patients.

Coconut oil and kernel flakes failed to induce favorable lipid changes comparable to coconut milk supplementation.

Coconut oil and kernel flakes may not be effective for improving lipid profiles compared to coconut milk.

The MC4R gene variant rs17782313 is directly associated with the risk of metabolic syndrome (MetS) in obese adults (B = 0.010; P = 0.023).

Genetic testing for the MC4R variant may help identify individuals at higher risk for metabolic syndrome.

Glycemic index (GI) and glycemic load (GL) mediate the relationship between the MC4R variant and LDL cholesterol (LDL-C) levels.

Dietary management focusing on GI and GL may help mitigate LDL-C levels in genetically susceptible individuals.

RIR rating accuracy did not significantly improve over time.

Practitioners should not expect RIR rating accuracy to improve significantly with time alone.

No competitor characteristic predicted any of the resistance training variables manipulated during peak week.

Competitors may not need to tailor their training adjustments based on individual characteristics during peak week.

There is a significant multiplicative interaction of cardiovascular autonomic neuropathy (CAN) and sex on both mortality outcomes.

Understanding the interaction between CAN and sex can improve risk assessment and management strategies in diabetes care.

Gastrointestinal adverse events (AEs) are common with incretin-based therapies (IBTs), with placebo-subtracted incidences of 5–39% for nausea, −7–39% for diarrhea, 2–31% for constipation, 0–26% for vomiting, and 2–20% for abdominal pain.

Clinicians should be aware of the high incidence of GI AEs when prescribing IBTs.

Most adverse events (AEs) associated with incretin-based therapies (IBTs) are mild or moderate and mainly occur during dose escalation.

Clinicians should monitor patients for mild to moderate AEs, especially during dose increases.

Only 2 out of 41 studies (approximately 5%) reported or assessed dietary intake or evaluated diet changes secondary to GLP-1/GIP RA medication use.

Practitioners should be aware of the lack of dietary assessment in studies involving GLP-1/GIP medications.

The quality of dietary assessment methods used in the studies was categorized as 'poor' and 'acceptable'.

Practitioners should consider the quality of dietary assessment methods when interpreting study results.

The review highlights a major gap in the evidence requiring urgent attention for high-quality research on dietary impacts of GLP-1/GIP medications.

There is a critical need for more rigorous studies to assess dietary changes associated with these medications.

Patients identified three risks associated with obesity treatment.

Understanding these risks can help healthcare providers address patient concerns and improve treatment uptake.

The uptake of obesity treatments remains disproportionally low in people living with the disease.

Healthcare providers should be aware of the low uptake to better engage patients in treatment options.